Intrathecal Morphine Infusion Therapy in Management of Chronic Pain: Present and Future Implementation in Korea
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Intrathecal morphine pump (ITMP) infusion therapy is efficient in managing malignant and nonmalignant chronic pain refractory to standard treatment. However, the high cost of an ITMP is the greatest barrier for starting a patient on ITMP infusiontherapy. Using the revised Korean reimbursement guidelines, we investigated the cost effectiveness of ITMP infusion therapyand conducted a patient survey. Materials and Methods: A retrospective chart review of 12 patients who underwent ITMP implantation was performed. Morphinedose escalation rates were calculated, and numeric rating scale (NRS) scores were compared before and after ITMP implantation. We surveyed patients who were already using an ITMP as well as those who were candidates for an ITMP. All survey data were collected through in-person interviews over 3 months. Data on the cost of medical treatment were collected and projectedover time. Results: The NRS score decreased during the follow-up period. The median morphine dose increased by 36.9% over the first year, and the median time required to reach a financial break-even point was 24.2 months. Patients were more satisfied with the efficacyof ITMP infusion therapy than with conventional therapy. The expected cost of ITMP implantation was KRW 4000000–5000000 in more than half of ITMP candidates scheduled to undergo implantation. Conclusion: The high cost of initiating ITMP infusion therapy is challenging; however, the present results may encourage more patients to consider ITMP therapy.
Abstract
Purpose: Intrathecal morphine pump (ITMP) infusion therapy is efficient in managing malignant and nonmalignant chronic pain refractory to standard treatment. However, the high cost of an ITMP is the greatest barrier for starting a patient on ITMP infusiontherapy. Using the revised Korean reimbursement guidelines, we investigated the cost effectiveness of ITMP infusion therapyand conducted a patient survey. Materials and Methods: A retrospective chart review of 12 patients who underwent ITMP implantation was performed. Morphinedose escalation rates were calculated, and numeric rating scale (NRS) scores were compared before and after ITMP implantation. We surveyed patients who were already using an ITMP as well as those who were candidates for an ITMP. All survey data were collected through in-person interviews over 3 months. Data on the cost of medical treatment were collected and projectedover time. Results: The NRS score decreased during the follow-up period. The median morphine dose increased by 36.9% over the first year, and the median time required to reach a financial break-even point was 24.2 months. Patients were more satisfied with the efficacyof ITMP infusion therapy than with conventional therapy. The expected cost of ITMP implantation was KRW 4000000–5000000 in more than half of ITMP candidates scheduled to undergo implantation. Conclusion: The high cost of initiating ITMP infusion therapy is challenging; however, the present results may encourage more patients to consider ITMP therapy.
참고문헌 (23)
- "Ministry of Health and Welfare"[URL]
- Jo HS, "Awareness of cancer and can-cer screening by Korean community residents", Asian Pac J Cancer Prev, 15, pp.4939~4944 (2014)
- Nuland SB, "Physician-assisted suicide and euthanasia in practice", N Engl J Med, 342, pp.583~584 (2000)
- Von Roenn JH, "A survey from the Eastern Cooperative Oncology Group", Ann Intern Med, 119, pp.121~126 (1993)
- Cleeland CS, "Undertreatment of cancer pain in elderly patients", JAMA, 279, pp.1914~1915 (1998)
- Wang JK, "Pain relief by intrathecally applied morphine in man", Anesthesiology, 50, pp.149~151 (1979)
- Wiffen PJ, "Oral morphine for cancer pain", Cochrane Database Syst Rev, 7, pp.CD003868~ (2013)
- Onofrio BM, "Treatment of chronic pain of malignant origin with intrathecal opiates", Clin Neurosurg, 31, pp.304~315 (1983)
- Nguyen H, "Cost-effectiveness of intraspinal drug delivery for chronic pain", Semin Pain Med, 2, pp.43~45 (2004)
- 이상진, "척수강 내 약물 주입기의 이식 −증례보고−", The Korean Journal of Pain, 22(1), pp.68~73 (2009), 대한통증학회
- Roberts LJ, "Outcome of intrathecal opioids in chronic non-cancer pain", Eur J Pain, 5, pp.353~361 (2001)
- Rauck RL, "Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain", J Pain, 4, pp.441~447 (2003)
- Upadhyay SP, "Intrathecal drug delivery system (IDDS) for cancer pain management: a review and updates", Am J Hosp Palliat Care, 29, pp.388~398 (2012)
- Deer TR, "Practice choices and challenges in the current intrathecal therapy environment: an online survey", Pain Med, 10, pp.304~309 (2009)
- Duarte RV, "A predictive model for intrathecal opioid dose escalation for chronic non-cancer pain", Pain Physician, 15, pp.363~369 (2012)
- Mekhail N, "Factors that might impact intrathecal drug delivery (IDD) dose escalation: a longitudinal study", Pain Pract, 14, pp.301~308 (2014)
- Foley KM, "The treatment of cancer pain", N Engl J Med, 313, pp.84~95 (1985)
- Atli A, "Intrathecal opioid therapy for chronic nonmalignant pain: a retrospective cohort study with 3-year follow-up", Pain Med, 11, pp.1010~1016 (2010)
- Malhotra VT, "Intrathecal pain pump infusions for intractable cancer pain:an algorithm for dosing without a neuraxial trial", Anesth Analg, 116, pp.1364~1370 (2013)
- Brogan SE, "A cost utilization analysis of intrathecal therapy for refractory cancer pain: identifying factors associated with cost benefit", Pain Med, 14, pp.478~486 (2013)
- Mueller-Schwefe G, "Cost effectiveness of intrathecal therapy for pain", Neuromodulation, 2, pp.77~87 (1999)
- Ver Donck A, "Intrathecal drug administration in chronic pain syndromes", Pain Pract, 14, pp.461~476 (2014)
- Hayek SM, "Intrathecal therapy for cancer and non-cancer pain", Pain Physician, 14, pp.219~248 (2011)